We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New Rapid 45-Minute COVID-19 Test Ideal for Screening at Points of Risk

By LabMedica International staff writers
Posted on 09 Jul 2020
Researchers at the Aikens Research Center at Beaumont Research Institute (Southfield, MI, USA) who developed the test found the results to be highly accurate as compared to existing technology. More...
Additionally, the rapid test is also relatively inexpensive to develop and operate as the materials for it are inexpensive and it does not require expensive machinery to run.

The researchers adapted the same technology for the COVID-19 test that they had come up with for a rapid, Zika virus detection test about three years ago. The detection test builds on recommendations from Anthony Fauci, M.D., immunologist and director of the National Institute of Allergy and Infectious Diseases since 1984, that rapid testing and tracing are the keys to containing the coronavirus. The researchers are now focusing on securing corporate sponsorship to fund development of the COVID-19 test.

According to Laura Lamb, Ph.D., who led the team, the test “could be used for screening at the point of risk, such as nursing homes, long-term care facilities, cruise ships, naval ships, within the school and prison systems, and by large employers, for example, at an Amazon warehouse or meatpacking plant. Because this is an existing test, we are optimistic with the right resources, it could be ready for widespread use within a month or so.”

Related Links:
Beaumont Research Institute


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.